Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: A case series

2011 ◽  
Vol 17 (1) ◽  
pp. 56-61 ◽  
Author(s):  
Jennifer L. Dotson ◽  
Wallace Crandall ◽  
Hayat Mousa ◽  
Jonathan R. Honegger ◽  
Lee Denson ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Case Series ◽  
Necrosis Factor Alpha ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel ◽  
Factor Alpha ◽  
Alpha Therapy ◽  
Necrosis Factor

Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries

2019 ◽  
Vol 25 (10) ◽  
pp. 1613-1620 ◽  
Author(s):  
Tawnya M Hansen ◽  
Laura E Targownik ◽  
Ahmer Karimuddin ◽  
Yvette Leung
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biologic Therapy ◽  
Preoperative Treatment ◽  
Necrosis Factor Alpha ◽  
Number Of Patients ◽  
Inflammatory Bowel ◽  
Factor Alpha ◽  
Alpha Therapy ◽  
Necrosis Factor

Abstract Increasing uptake of biologic therapy has contributed to declining surgical rates for inflammatory bowel disease (IBD). However, a significant number of patients on biologic therapy will go on to require surgery. The literature is conflicted with regard to the preoperative management of biologic therapy before urgent or elective IBD surgery. This article reviews the available data on postoperative complications following preoperative treatment with anti-tumor necrosis factor alpha therapy, anti-integrin therapy, and anti-interleukin therapy.

Sign in / Sign up

Export Citation Format

Share Document